Mohammed Qatanani
Chief Tech/Sci/R&D Officer bij SCHOLAR ROCK HOLDING CORPORATION
Vermogen: 3 M $ op 31-03-2024
Profiel
Mohammed Qatanani is currently the Chief Scientific Officer at Scholar Rock Holding Corp.
He previously worked as the Director-Discovery Research at Alexion Pharmaceuticals, Inc. from 2015 to 2018 and as the Vice President-Program & Alliance Management at Dyne Therapeutics, Inc. from 2018 to 2021.
Dr. Qatanani completed his undergraduate and graduate degrees at the American University of Beirut and holds an MBA from Baylor College of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-02-2024 | 147 019 ( 0.19% ) | 3 M $ | 31-03-2024 |
Actieve functies van Mohammed Qatanani
| Bedrijven | Functie | Begin |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Chief Tech/Sci/R&D Officer | 01-09-2022 |
Eerdere bekende functies van Mohammed Qatanani
| Bedrijven | Functie | Einde |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-09-2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2018 |
Opleiding van Mohammed Qatanani
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
